Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that acts on the proximal tubule to decrease phosphate reabsorption and serum levels of 1,25-dihydroxyvitamin D3 [1,25(OH)2 Vitamin D3]. Abnormal FGF23 metabolism has been implicated in several debilitating hypophosphatemic and hyperphosphatemic disorders. The renal receptors responsible for the phosphaturic actions of FGF23 have not been elucidated. There are four fibroblast growth factor receptors (FGFR); 1-4 with "b" and "c" isoforms for receptors 1, 2, and 3. FGFR1, 3, and 4 are expressed in the mouse proximal tubule, and deletion of any one receptor did not affect serum phosphate levels, suggesting that more than one receptor is involved in mediating the phosphaturic actions of FGF23. To determine the receptors responsible for the phosphaturic actions of FGF23, we studied Fgfr1 (kidney conditional) and 
mice have elevated serum phosphorus levels, increased brush-border membrane vesicle (BBMV) phosphate transport, and increased Na-Pi cotransporter 2c (NaPi-2c) protein expression compared with wildtype mice. These data are consistent with FGFR1 and FGFR4 being the critical receptors for the phosphaturic actions of FGF23. FGF receptors; fibroblast growth factor 23; phosphate; vitamin D; proximal tubule FIBROBLAST GROWTH FACTOR 23 (FGF23) is a bone-derived hormone that plays an important role in phosphate and vitamin D homeostasis. Dysregulation of FGF23 results in several inherited and acquired disorders of phosphate homeostasis (4, 6, 13) . FGF23 inhibits renal phosphate reabsorption by decreasing brush border expression of the sodium-phosphate cotransporters 2a and 2c (NaPi-2a and NaPi-2c) in the kidney (12, 42) . In addition, FGF23 decreases serum levels of 1,25(OH) 2 Vitamin D 3 by decreasing 1␣-hydroxylase (CYP27b1), the enzyme responsible for conversion of 25(OH) 2 Vitamin D 3 to 1,25(OH) 2 Vitamin D 3 and by increasing 24-hydroxylase (CYP24), the enzyme responsible for the catabolism of 1,25(OH) 2 Vitamin D 3 (37, 42) . The hypophosphatemic disorders where FGF23 levels are elevated include tumor-induced osteomalacia, X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, and autosomal dominant hypophosphatemic rickets (5, 10, 12, 18, 21, 29, 35, 47) . Elevated FGF23 levels result in hypophosphatemia, inappropriately normal or low 1,25(OH) 2 Vitamin D 3 levels, rickets/osteomalacia, fractures, and bone pain. The hyperphosphatemic disorders where FGF23 levels are low include tumoral calcinosis, where patients have severe hyperphosphatemia, elevated 1,25(OH) 2 Vitamin D 3 levels, and painful calcifications of the soft tissues and joints (19) . Elevated FGF23 levels in patients with chronic kidney disease and end-stage renal disease have been associated with increased morbidity and mortality (16, 20) . Additionally, FGF23 has been shown to induce left ventricular hypertrophy (9) .
Fibroblast growth factor family members are known to bind to four known fibroblast growth factor receptors (FGFRs) and initiate intracellular signaling (8, 33) . The four FGFRs are numbered 1-4 and are coded by four genes. Alternative splicing of FGFR1, 2, and 3 results in a total of seven isoforms, and these seven FGFRs have ligand binding specificity (32, 34) . FGFR2 does not bind to FGF23 and is not present in the proximal tubule (12, 28) . Previous data from our laboratory suggested that deletion of a single FGFR was not responsible for the phosphaturic actions of FGF23 (12) . However, kidney conditional Fgfr1 Ϫ/Ϫ mice and global Fgfr4 Ϫ/Ϫ mice had an ϳ1.4-fold increase in FGF23 levels at baseline compared with wild-type mice and had comparable serum phosphorus levels to wild-type mice. In response to exogenously administered pharmacological doses of FGF23, kidney conditional Fgfr1 Ϫ/Ϫ mice did not become hypophosphatemic and Fgfr4 Ϫ/Ϫ mice had an attenuated hypophosphatemic response compared with wild-type mice (12) . To determine whether FGFR1 and FGFR4 together were the joint renal receptors for FGF23, we examined phosphate homeostasis in Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice.
METHODS

Generation of Fgfr1
We have previously studied individual kidney conditional Fgfr1 Ϫ/Ϫ and Fgfr4 Ϫ/Ϫ mice (12). As previously described, Fgfr4 Ϫ/Ϫ mice are from a mixed 129/Black Swiss background.
Conditional Fgfr1
Ϫ/Ϫ mice were generated using the lox-p/cre recombinase technique as global Fgfr1 Ϫ/Ϫ mice are embryonically lethal and are from mixed 129/Sv and C57BL/6J backgrounds as previously described (7, 12, 17, 26, 38) . Pax3 cre recombinase is expressed in the metanephric mesenchyme and not in the ureteric bud (7). Mice expressing Pax3 cre when mated with mice that have the Fgfr1 gene flanked by lox-p sites will generate mice that have Fgfr1 deleted from the metanephric mesenchyme. Metanephric mesenchyme gives rise to nephron segments from the proximal tubule, the primary site of phosphate reabsorption (2) , to the distal convoluted tubule (30 mice, and the data were similar to the data obtained from the wild-type littermates described above (not shown). The mice were genotyped before the study and were studied at 2.5-4 mo of age. The mice were cared for at the animal facility at the University of Texas Southwestern Medical Center where the mice were on a 12:12-h day-night cycle. The mice were fed on a Teklad Global 16% protein standard rodent diet (TD 2016), and they were given free access to food and water. Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice. The kidneys were harvested 1 h after the injection, and whole kidney total protein was obtained by homogenization using a Potter Ejevhem homogenizer as described below. Total protein was used to study MAPK signaling. Vehicle-injected mice were studied for baseline phosphorylation of MAPK.
Serum and urine biochemical parameters. Mice were sedated using isoflurane, and retro-orbital venipuncture was performed to obtain blood. Serum was separated and snap frozen in liquid nitrogen and stored at Ϫ80°C in aliquots until the various assays were performed. The manufacturer's instructions were followed for all the assays described below. Serum phosphorus was measured using a colorimetric assay (Phosphorus Liqui-UV Test, Stanbio Laboratories, Boerne, TX). Serum 1,25(OH)2D3 levels were measured using the ELISA technique with a 1,25-Dihydroxy Vitamin D EIA kit (Immunodiagnostic Systems, Scottsdale, AZ). Serum parathyroid hormone (PTH) levels were measured using an Intact Mouse PTH EIA kit (Immutopics, San Clemente, CA). Serum FGF23 levels were measured using an Intact FGF23 EIA kit (Kainos Laboratories).
Brush-border membrane vesicle isolation. The kidneys were harvested and placed in ice-cold PBS. The whole kidney and renal cortex was homogenized separately using a Potter Ejevhem homogenizer at 4°C in isolation buffer containing 5 mM EGTA, 16 mM HEPES, 300 mM mannitol titrated to pH 7.4 with Tris, protease inhibitor cocktail (1:1,000, Sigma, St. Louis, MO), and 100 g/l PMSF (Sigma). Brush border membrane vesicles (BBMVs) were isolated from the renal cortex only as previously described in our laboratory using magnesium precipitation and differential centrifugation (12, 14) .
Immunoblotting. Twenty-five to 50 g of either BBMVs or whole kidney lysate were first diluted with SDS-PAGE loading buffer. Whole kidney lysate was denatured at 65°C for Klotho and at 37°C for pMAPK/MAPK, and BBMVs were denatured at 37°C before being fractionated on a 8% SDS-polyacrylamide gel as described previously (12) . Protein was transferred over 1.5 h at 4°C at 350 -450 mA to a polyvinylidene difluoride membrane (PVDF). Blotto (5% nonfat milk in PBS) was used to block the PVDF membrane for at least 1 h before the membrane was probed with primary antibodies to Klotho (1: 4,000), pMAPK (1:1,000), MAPK (1:1,000), NaPi-2a (1:5,000), or NaPi-2c (1:500) at 4°C for at least 12-16 h. The Klotho antibody was a generous gift from Dr. M. Kuro-O at the University of Texas Southwestern Medical Center. NaPi-2a and NaPi-2c antibodies were generous gifts from Dr. M. Levi (University of Colorado). Activation of the MAPK signaling pathway after FGF23 administration was assessed by using antibodies to pMAPK/MAPK (Cell Signaling, Danvers, MA). After incubation with the primary antibody, the PVDF membranes were washed multiple times with PBS containing Tween 20 (0.1%) and then incubated with the secondary anti-rat antibody (Klotho) at 1:3,000 and secondary anti-rabbit (NaPi-2a and NaPi-2c,1: 15,000) and pMAPK/MAPK at 1:5,000 dilution for 1 h. Enhanced chemiluminescence (Amersham Life Sciences) reagent was used to detect the bound antibody. ␤-Actin at 1:15,000 dilution was used as a loading control (Sigma Biochemicals). Scion Image software (Frederick, MD) was used to quantify the protein abundance.
Sodium-dependent BBMV phosphate transport activity. The rapid Millipore filtration technique was employed to measure sodiumdependent phosphate ( 32 P) transport in BBMVs. The intravesicular buffer (300 mM mannitol and 16 mM HEPES titrated to a pH of 7.5 using Tris) was used to suspend BBMVs, and 100 g (10 l) of BBMVs were used to assay phosphate transport. BBMVs were then mixed with extravesicular buffer (90 l) (150 mM NaCl and 16 mM HEPES, 0.1 mM KH 2PO4 titrated to a pH 7.5 with Tris) as previously described (1, 39) . Phosphate uptake was terminated at 20 s by using ice-cold stop solution (135 mM NaCl, 16 mM HEPES, 10 mM sodium arsenate, pH 7.5), and 0.45-m filters were used to filter the resulting solution (Millipore, Billerica, MA). The uptake measurements were performed at least in triplicate.
Metabolic studies. Mice were first acclimatized to metabolic cages (Hatteras Instruments, Hatteras, NC) with free access to food and water for 3 days. After acclimatization, 24-h food intake was measured and 24-h stool was collected to estimate gastrointestinal phosphate absorption. The TD 2016 standard diet has 0.7 g of phosphate/ 100 g of diet (Harlan Laboratories, Madison, WI). Twenty-four-hour stool samples were first dissolved by incubation at 95°C for 12-14 h in the presence of 2 ml of 1.2 M nitric acid. Each sample was then diluted and solubilized with 5 ml of water (3). The supernatant was collected, and stool phosphorus was measured using the Fiske and Subbarow method (11) .
RNA isolation and quantitative PCR. Kidneys were homogenized in lysis solution, and RNA was extracted using a GenElute mammalian total RNA kit (Sigma-Aldrich, St. Louis, MO). Calvarial bones were harvested and frozen in liquid nitrogen until further assay. TRIzol was used to extract RNA from the bones. RNA quality and purity were determined before cDNA synthesis. cDNA was synthesized from 4 g of RNA as per kit instructions from the ThermoScript RT-PCR System (Invitrogen Life Technologies, Grand Island, NY). GAPDH primers were used to verify cDNA synthesis. An iCycler PCR Thermal cycler (Bio-Rad, Hercules, CA) was used to carry out quantitative PCR. Taqman gene expression assay and universal master mix were used to quantify Klotho mRNA expression. Fgf23, NaPi-2a, NaPi-2c, and 28S mRNA expression were quantified using SYBR Green master mix (Bio-Rad). The following primer sequences were used: FGF23, forward 5=-TTT CCC AGG TTC GTC TAG G-3= and reverse 5=-CTC GCA GGT GAC TCT CAG-3= (45); NaPi-2a, forward 5=-CAA TGC CAT CCT ATC CAA CC-3= and reverse 5=-GAC CAT GCT GAC AAT GAT GG-3=; and NaPi-2c, forward 5=-ATC TCC GGT TCC ATT CCA GG-3= and reverse 5=-GTA GAG GCT TCC CAG GAG TC-3=. The housekeeping gene 28S was used, and the primer sequences for 28S were (forward) 5=-TTG AAA ATC CGG GGG AGA G-3= and (reverse) 5=-ACA TTG TTC CAA CAT GCC AG-3=.
Statistical analysis. All data are expressed as means Ϯ SE. Student's t-test was used to assess the difference between two groups. ANOVA was employed to study the differences between multiple groups with a post hoc Student-Newman-Keuls test. A P value Ͻ0.05 was considered significant.
RESULTS
Baseline characteristics. It was our hypothesis that FGFR1 and FGFR4 are the critical receptors for the phosphaturic actions of FGF23. Thus we examined whether deletion of both Fgfr1 and Fgfr4 in the kidney would result in hyperphosphatemia, demonstrating resistance to FGF23. In Table 1 We next examined the cause for the increase in serum phosphorus despite an increase in FGF23. In Fig. 1 , we show that BBMV phosphate transport was increased in Fgfr1 Ϫ/Ϫ / Fgfr4 Ϫ/Ϫ mice compared with wild-type and Fgfr4 Ϫ/Ϫ mice. We next compared BBMV NaPi-2a and NaPi-2c protein abundance to determine whether either of the proximal tubule brush border transporters had increased protein expression. NaPi-2c protein expression relative to ␤-actin was increased in Fgfr1
Ϫ/Ϫ mice compared with both wild-type and Fgfr4 Ϫ/Ϫ mice (Fig. 2) , while NaPi-2a protein expression was comparable in wild-type, Fgfr1
, and Fgfr4 Ϫ/Ϫ mice (Fig. 3) . The relative mRNA expression of NaPi-2a/28s and NaPi-2c/28s was comparable in wild-type and Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice (Fig. 4, A and B) 
/Fgfr4
Ϫ/Ϫ mice. 
Ϫ/Ϫ mice as shown in Fig. 6 . We next examined the effects of exogenous administration of mouse recombinant FGF23 on intracellular signaling of FGF23. As shown in Fig. 7 , wild-type mice demonstrated increased pMAPK protein abundance 1 h after receiving recombinant FGF23, while Fgfr1
Ϫ/Ϫ mice did not demonstrate increased pMPAK protein abundance (Fig. 7) .
Since Klotho is a cofactor for the interaction of FGF23 and its receptor, and Klotho Ϫ/Ϫ mice have elevated FGF23 levels, we measured Klotho protein and mRNA expression in the kidney. Both relative Klotho mRNA expression (Fig. 8A) and Klotho protein expression from whole kidney lysate were not different in wild-type and Fgfr1
Ϫ/Ϫ
/Fgfr4
Ϫ/Ϫ mice (Fig. 8B) . We studied the role of a phosphate-depleted diet on serum FGF23 levels in wild-type and Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice. After 5 days on a phosphate-depleted diet, serum phosphorus in the animals was comparable in wild-type and Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice ( Fig. 9A ), but serum FGF23 levels remained elevated in Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice (Fig. 9B ). In summary, Fgfr1
Ϫ/Ϫ mice have elevated serum FGF23 levels compared with wild-type mice, and the elevated levels are likely due to increased synthesis of FGF23 from bone. Despite the elevated FGF23 levels, serum phosphorus levels are increased in Fgfr1
Ϫ/Ϫ mice compared with wild-type mice, demonstrating resistance to phosphaturic actions of FGF23. In addition, there is abrogation of intracellular signaling of FGF23 in Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice. These results are consistent with our hypothesis that FGFR1 and FGFR4 are the primary receptors for the phosphaturic actions of FGF23. Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice the likely source of elevated FGF23 levels is increased production from bone. The expression of Klotho, an important cofactor for the interaction of FGF23 with its receptors, was comparable in wildtype and Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice. These data together demonstrate that FGFR1 and FGFR4 are critical receptors for the renal phosphaturic effects of FGF23.
Identification of the FGFRs responsible for the various actions of FGF23 has been a topic of significant interest (12, 15, 25, 28, 48) . Results from in vitro studies employing cell , and kidneys were harvested 1 h later. Phosphorylation of MAPK (pMAPK) was assessed in total kidney homogenate; 50 g of whole kidney lysate was fractionated on 8% SDS gels. There was an increase in MAPK phosphorylation in wild-type mice but not in Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice.
lines to identify the receptors for FGF23 have been controversial, with one study demonstrating the binding of FGF23 to only FGFR1 in the presence of Klotho (46) (27) . PTH has been shown to increase FGF23 levels, as seen in a mouse model of hyperparathyroidism (22) and in patients with Jansen's metaphyseal chondrodysplasia due to activating mutations of the PTH/PTHrelated peptide receptor (41) . In addition, parathyroidectomy in mice with early chronic kidney disease decreased FGF23 levels (24) . In our study, serum PTH levels were lower in Fgfr1 Ϫ/Ϫ / Fgfr4 Ϫ/Ϫ mice than wild-type mice and thus are not contributing to the elevated FGF23 levels in Fgfr1
Ϫ/Ϫ mice. Previous studies have examined the role of changes in dietary phosphorus in the regulation of FGF23. Changing the dietary phosphate content of mice from 0.02 to 1.6% resulted in a change in serum phosphorus from 3.7 to 9.3 mg/dl while the FGF23 levels increased from 9.3 to 65 pg/ml. Thus a 2.5-fold change in serum phosphorus resulted in a 7-fold increase in FGF23 levels (36) . Of note, the total body phosphate content and changes in serum phosphorus could have differing roles in their regulation of serum FGF23 level. In Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice, FGF23 levels are ϳ50-fold higher compared with wild-type mice in the face of a 30% increase in serum phosphorus levels in Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice. In response to a phosphate-depleted diet, serum phosphorus levels decrease in wild-type and Fgfr1
Ϫ/Ϫ
/Fgfr4
Ϫ/Ϫ mice to comparable levels. In animals on a phosphate-depleted diet, serum FGF23 levels also decrease in WT and Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice, but serum FGF23 levels still remained elevated in Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice compared with wild-type mice. Thus the serum phosphorus level in Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice is not the sole factor contributing to the elevated FGF23 levels in Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice. As in early chronic kidney disease, the factors regulating the elevated FGF23 levels in Fgfr1 Ϫ/Ϫ / Fgfr4 Ϫ/Ϫ mice are unclear at this time. There are several hypotheses that have been put forth for elevated FGF23 levels in early chronic kidney disease, including Klotho deficiency and an increase in total body phosphorus that is not reflected by an increase in serum phosphorus levels. However, these are speculative, and further work is needed to identify the regulatory factors for elevated FGF23.
It is intriguing that Fgfr1 Ϫ/Ϫ /Fgfr4 Ϫ/Ϫ mice have significantly elevated serum FGF23 levels, and it appears that the well-known regulators of FGF23 alone do not appear to be the culprits. From our data, it is also apparent that FGF23 is synthesized in bone, and there is likely kidney-to-bone cross talk, as the kidney is the only organ in this mouse model with deletion of both Fgfr1 and Fgfr4. Recently, the use of FGFR1 blockers in bone marrow stem cells in Hyp mice has been shown to decrease Fgf23 mRNA expression, indicating that FGFR1 plays a role in regulating FGF23 expression (31 
